611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Why Your Nose May Be Key to Parkinson's RiskEvolution Not Over for HumansBrain Scans Offer Clues to Why Some Teens Pile on PoundsNew Clues to Why Yawns Are ContagiousNew Hope From Old Drugs in Fight Against Parkinson'sFirst Gene Therapy Approved in U.S.Awake for Aneurysm Brain Surgery, Better Results?Does Autism Risk Reside in Cells' Energy Engines?More Evidence Contact Sports Can Affect the BrainVirtual House Calls for Speedy, Effective Parkinson's CareSeven Imaging Biomarkers Tied to Cognition in Male FightersDiabetes Drug Shows Promise Against Parkinson'sCombined MRI Might Help Predict Brain Damage in BoxersMedical Reality Catches Up to Science FictionNoninvasive Brain Test May Pinpoint Type of DementiaIn Mice, Brain Cells Discovered That Might Control AgingScans May Show Consciousness in 'Comatose' PatientsBoxers, MMA Fighters May Face Long-Term Harm to Brain: StudyFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Early Parkinson's May Prompt Vision ProblemsWhole-Genome Sequencing of Uncertain Clinical UtilityCould Shift Work Damage Your DNA?Gene Sequencing May Reveal Risks for Rare DiseasesRogue Genes May Cause Some ALS CasesSticky Brain 'Plaques' Implicated in Alzheimer's AgainEven Your Bones Can Get Fat, Mouse Study SuggestsDoes a Low-Fat Dairy Habit Boost Parkinson's Risk?MicroRNA Biomarker Signature Identified for Allergic AsthmaHaywire Immune Cells May Help Cause BaldnessRegion in Brain Associated With Fear of Uncertain FutureBrain Scans Spot Where Fear and Anxiety LiveGene Therapy Might Someday Mend Badly Broken BonesLife Expectancy Slighter Shorter With Parkinson's, DementiaStudy Looks at Parkinson's Effect on Life SpanBody Cooling May Help Brain After Cardiac ArrestDo You Overeat? Your Brain Wiring May Be WhyGene Mutation May Speed Alzheimer's DeclineIs This Enzyme Making You Fat?Type 2 Diabetes May Be Bad for Brain Health'Brain Age' May Help Predict When You'll DieParkinson's Disease May Originate in Gut, Study SaysBlood-Based Genome Testing Feasible for Rapid Mutation AssayBlood Test May Gauge Death Risk After Surgery150-Year-Old Drug May Shorten 'Off' Time for Parkinson's PatientsBrain May Be Organized by Functions, Not Body PartsBody Temperature Might Give Clues to ComaCould Young Blood Boost the Aging Brain?A 'Brainwave' to Help Fight PTSDDizziness in Parkinson's May Be Due to Cerebral HypoperfusionMisunderstood Gene Tests May Lead to Unnecessary Mastectomies
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Gene Therapy Shows Promise for Aggressive Lymphoma

HealthDay News
by -- Margaret Farley Steele
Updated: Feb 28th 2017

new article illustration

TUESDAY, Feb. 28, 2017 (HealthDay News) -- An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report.

Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif.

These patients had not responded to usual treatments and had no other options, Kite said Tuesday in a news release.

Overall, more than four out of five patients with the blood cancer saw their cancer reduced by more than half for at least part of the study, the company said.

"This seems extraordinary ... extremely encouraging," one cancer specialist, Dr. Roy Herbst, told the Associated Press.

But Herbst, who is chief of medical oncology at Yale Cancer Center in New Haven, Conn., said longer follow-up is needed to see if the benefit continues.

Still, he said, "This certainly is something I would want to have available." Side effects, which had been a concern, seemed manageable in this study, he said.

The therapy -- called CAR-T cell therapy -- enables the patient's own blood cells to kill the cancer cells.

Lymphoma is a general term for cancers that begin in the lymph system. The lymph system is part of the immune system, which helps the body fight disease.

Here's how the treatment works: A patient's blood is filtered so immune cells called T-cells can be altered to contain a cancer-fighting gene. The cells are returned to the patient intravenously, and the cancer-targeting cells then multiply in the patient's body.

The U.S. National Cancer Institute developed the gene approach and licensed it to Kite. Now, Kite and another pharmaceutical giant, Novartis AG, are competing to gain approval of the treatment, according to the AP.

Kite reportedly intends to seek U.S. Food and Drug Administration approval this spring and approval in Europe later this year. It could be the first gene therapy approved in the United States, the news report noted.

Although the therapy appears to benefit a significant number of patients, it is not risk-free. Researchers believe two patients died of treatment-related causes, the AP reported.

Other side effects included anemia or other blood problems that were treated, and neurological problems such as sleepiness, confusion, tremor or difficulty speaking, which typically lasted only a few days, the wire service reported.

Overall, however, the therapy seems safe, according to Dr. Steven Rosenberg, chief of surgery branch at the National Cancer Institute. He was not involved with the study.

"It's a safe treatment, certainly a lot safer than having progressive lymphoma," Rosenberg told the AP. He said he has a patient who was treated this way who is still in remission seven years later.

The cost of such treatment hasn't been reported yet, but immune system therapies tend to be very expensive.

The results are scheduled for presentation at the American Association for Cancer Research conference in April. Until published in a peer-reviewed medical journal, the data and conclusions should be considered preliminary.

More information

The U.S. National Cancer Institute has more about lymphoma.